HUTCHMED (China) (HCM) Cash from Investing Activities (2018 - 2021)
HUTCHMED (China) (HCM) posted quarterly Cash from Investing Activities of -$315.9 million for Q2 2021, down 665.3% year-over-year from $55.9 million in Q2 2020, and down 297.41% quarter-over-quarter from $160.0 million in Q1 2021.
HUTCHMED (China) (HCM) Cash from Investing Activities (2018 - 2021) Analysis & Trends
HUTCHMED (China) (HCM) has reported Cash from Investing Activities for 4 consecutive years, with -$315.9 million the latest figure, recorded in Q2 2021.
- In Q2 2021, Cash from Investing Activities fell 665.3% year-over-year to -$315.9 million; the TTM figure through Jun 2021 stood at -$295.0 million (down 281.98% YoY), while the FY2025 annual figure was -$3.8 million, up 69.28% from the prior year.
- Cash from Investing Activities fell to -$315.9 million in Q2 2021 per HCM's latest filing, from $160.0 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $160.0 million in Q1 2021 and bottomed at -$315.9 million in Q2 2021.
- Historically, Cash from Investing Activities has averaged -$11.0 million across 4 years, with a median of $19.0 million in 2019.
- Annual changes were most pronounced in 2019 — Cash from Investing Activities surged 299.29% — and 2021, when it tumbled 665.3%.
- HUTCHMED (China)'s Cash from Investing Activities stood at -$15.3 million in 2018, then jumped by 193.2% to $14.2 million in 2019, then slumped by 390.3% to -$41.3 million in 2020, then sank by 665.3% to -$315.9 million in 2021.
- Business Quant data shows HCM's Cash from Investing Activities at -$315.9 million in Q2 2021, $160.0 million in Q1 2021, and -$41.3 million in Q2 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | HUTCHMED (China) | 2.19 Bn | 2.19 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -315.92 Mn |
| Jun 30, 2021 | -315.92 Mn |
| Mar 31, 2021 | 160.04 Mn |
| Mar 31, 2021 | 160.04 Mn |
| Jun 30, 2020 | -41.28 Mn |
| Jun 30, 2020 | -41.28 Mn |
| Mar 31, 2020 | -97.84 Mn |
| Mar 31, 2020 | -97.84 Mn |
| Dec 31, 2019 | 14.22 Mn |
| Dec 31, 2019 | 14.22 Mn |
| Sep 30, 2019 | 47.67 Mn |
| Sep 30, 2019 | 47.67 Mn |
| Jun 30, 2019 | 23.76 Mn |
| Jun 30, 2019 | 23.76 Mn |
| Mar 31, 2019 | 33.38 Mn |
| Mar 31, 2019 | 33.38 Mn |
| Dec 31, 2018 | -15.26 Mn |
| Dec 31, 2018 | -15.26 Mn |
| Sep 30, 2018 | 43.22 Mn |
| Sep 30, 2018 | 43.22 Mn |